Why localization matters, the human evidence behind our approach, and the design of KIN-112.
Innate immunity can initiate and coordinate powerful antitumor responses, but activating it throughout the body may cause inflammatory toxicities that limit treatment. Kinimmune is developing therapies designed to concentrate immune activation at the site of disease while limiting unnecessary systemic exposure.
Kinimmune’s approach builds on a completed 9-patient window-of-opportunity study in which glatiramer acetate was administered locally before planned tumor surgery. Pre- and post-treatment tissue analysis demonstrated clinical feasibility and identified treatment-associated changes in tumor immune biology. Kinimmune has translated this foundation into a defined, next-generation glatiramoid designed for greater precision, consistency, and developability.
KIN-112 combines Kinimmune’s proprietary next-generation glatiramoid with a TLR9 agonist. The components form complexes designed to remain at the treatment site, engage local immune cells, and focus potent innate immune activation within tumor tissue.
KIN-112 is the lead application of Kinimmune’s broader expertise in peptide design, immune signaling, and tissue localization.